REPLIGEN CORP

Repligen’s CEO’s RSU grant signals executive confidence, linking insider holdings to a new bioprocessing acquisition and long‑term shareholder value.

CEO insider trades on Oct 5: disciplined sales and options under a Rule 10b‑5‑1 plan, minimal market impact, but keep an eye on bioprocessing milestones and earnings for valuation shifts.

CEO Olivier Loeillot’s 10b5‑1 trades show disciplined rebalancing, not panic selling, boosting confidence in REPLIGEN’s high‑growth outlook.